Answers are grounded in this paper and cite their sources.
Review highlights the therapeutic potential of targeting BAFF and BAFF-R in autoimmune cytopenias, indicating a promising approach to overcome transient treatment responses.
Current treatments for immune thrombocytopenia (ITP) and warm autoimmune hemolytic anemia (wAIHA), rare autoimmune diseases in which autoreactive B cells play a major role, can lead to high response rates; however, for many patients these responses are not durable or maintained after treatment discontinuation. Binding of B-cell-activating factor (BAFF) to its receptor (BAFF-R) has been shown to lead to B-cell differentiation, proliferation, and survival, with BAFF levels shown to be elevated in patients with ITP and wAIHA. Targeting the BAFF/BAFF-R pathway could address unmet needs that remain for patients with ITP and wAIHA despite available treatments.
No takes yet. Share an insight, caveat, or question.
Mahévas et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: